Earnings ·
Faeth Therapeutics reported second quarter 2026 financial results and operational updates following its merger with…
SNSESensei Biotherapeutics, Inc.
Faeth Therapeutics reported second quarter 2026 financial results and operational updates following its merger with Sensei Biotherapeutics and a concurrent $200 million PIPE financing. Cash, cash equivalents, and marketable securities increased to $186.4 million from $21.2 million at year-end 2025. Research and development expenses rose to $9.2 million from $2.5 million in the prior-year quarter, while general and administrative expenses reached $9.2 million compared to $2.7 million. The company reported a net loss of $16.0 million, or $2.84 per share, against a net loss of $4.9 million, or $3.91 per share, in the same period last year. Operational highlights include the first patient dosed in the Phase 1b/2 PIK-101 trial for HR+ breast cancer and expectations for topline data from the Phase 2 PIK-201 endometrial cancer trial by year-end. Faeth Therapeutics is a clinical-stage biotechnology company developing oncology treatments targeting the PI3K/AKT/mTOR pathway.